TechCrunch — Axon Technology, Dexona, and a host of other medical and health technology companies will be joining together to raise a $500 million Series B round.
Axon will also invest in another $500m Series B, Axon Health Sciences, which aims to accelerate the development of a novel medical technology to treat and prevent heart disease, diabetes, and other chronic conditions.
Axon will invest in AxonHealth Sciences and Axon Medicine.
Axons main investors include Fidelity, New Enterprise Associates, and FirstMark Capital.
The deal was announced today in a press release from Axon.
Axona’s CEO and cofounder, Dr. James D. Caulfield, said in a statement that “our mission is to revolutionize the way we care for patients and promote optimal health.
We have been fortunate to collaborate with industry leaders to create a product that can be used to solve these problems.
With this new investment, Axons founders will have access to additional resources to help accelerate the product’s development and bring it to market.”
Axon Health’s chief executive officer, Drs.
William F. McManus and David B. Koehler, said, “We are excited to partner with Axon Technologies to bring our team together to build on this vision and accelerate the advancement of the Axon technology to patients, health care providers, and the broader healthcare industry.”
Axons research arm, Axonal Research, will be focusing on the development and commercialization of new treatments and medical devices that can treat and alleviate chronic diseases.
Axonal is the only company in the medical device space to focus on heart disease and diabetes, Axoni, and others.